Choong Ang Vaccine Laboratory Co. Ltd (072020) - Net Assets
Based on the latest financial reports, Choong Ang Vaccine Laboratory Co. Ltd (072020) has net assets worth ₩104.72 Billion KRW (≈ $70.97 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩122.80 Billion ≈ $83.22 Million USD) and total liabilities (₩18.08 Billion ≈ $12.25 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Choong Ang Vaccine Laboratory Co. Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩104.72 Billion |
| % of Total Assets | 85.28% |
| Annual Growth Rate | 7.16% |
| 5-Year Change | 18.64% |
| 10-Year Change | 89.26% |
| Growth Volatility | 8.37 |
Choong Ang Vaccine Laboratory Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Choong Ang Vaccine Laboratory Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Choong Ang Vaccine Laboratory Co. Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Choong Ang Vaccine Laboratory Co. Ltd (2014–2024)
The table below shows the annual net assets of Choong Ang Vaccine Laboratory Co. Ltd from 2014 to 2024. For live valuation and market cap data, see Choong Ang Vaccine Laboratory Co. Ltd (072020) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩103.87 Billion ≈ $70.39 Million |
+4.07% |
| 2023-12-31 | ₩99.80 Billion ≈ $67.64 Million |
+4.72% |
| 2022-12-31 | ₩95.30 Billion ≈ $64.59 Million |
+2.50% |
| 2021-12-31 | ₩92.98 Billion ≈ $63.01 Million |
+6.20% |
| 2020-12-31 | ₩87.55 Billion ≈ $59.33 Million |
+1.37% |
| 2019-12-31 | ₩86.37 Billion ≈ $58.53 Million |
+1.60% |
| 2018-12-31 | ₩85.00 Billion ≈ $57.61 Million |
+31.43% |
| 2017-12-31 | ₩64.68 Billion ≈ $43.83 Million |
+7.14% |
| 2016-12-31 | ₩60.37 Billion ≈ $40.91 Million |
+9.99% |
| 2015-12-31 | ₩54.88 Billion ≈ $37.19 Million |
+5.56% |
| 2014-12-31 | ₩51.99 Billion ≈ $35.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Choong Ang Vaccine Laboratory Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 92.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩74.06 Billion | 71.31% |
| Common Stock | ₩4.98 Billion | 4.79% |
| Other Components | ₩24.82 Billion | 23.90% |
| Total Equity | ₩103.87 Billion | 100.00% |
Choong Ang Vaccine Laboratory Co. Ltd Competitors by Market Cap
The table below lists competitors of Choong Ang Vaccine Laboratory Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yatra Online Inc
NASDAQ:YTRA
|
$63.94 Million |
|
FineMat Applied Materials Co Ltd
TW:6698
|
$63.94 Million |
|
Park Elektrik Uretim Madencilik Sanayi ve Ticaret AS
IS:PRKME
|
$63.95 Million |
|
Digital Multimedia Technology Co.Ltd
KQ:134580
|
$63.96 Million |
|
Jayant Agro Organics Limited
NSE:JAYAGROGN
|
$63.91 Million |
|
Fluence Corporation Ltd
AU:FLC
|
$63.89 Million |
|
Kingstate Electronics
TWO:3206
|
$63.85 Million |
|
Southland Holdings Inc.
NYSE MKT:SLND
|
$63.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Choong Ang Vaccine Laboratory Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 99,804,215,410 to 103,867,274,100, a change of 4,063,058,690 (4.1%).
- Net income of 6,850,008,330 contributed positively to equity growth.
- Dividend payments of 1,448,803,050 reduced retained earnings.
- Share repurchases of 1,080,396,350 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩6.85 Billion | +6.59% |
| Dividends Paid | ₩1.45 Billion | -1.39% |
| Share Repurchases | ₩1.08 Billion | -1.04% |
| Other Changes | ₩-257.75 Million | -0.25% |
| Total Change | ₩- | 4.07% |
Book Value vs Market Value Analysis
This analysis compares Choong Ang Vaccine Laboratory Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.93x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.52x to 0.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩6651.35 | ₩10080.00 | x |
| 2017-12-31 | ₩7126.31 | ₩10080.00 | x |
| 2018-12-31 | ₩8535.70 | ₩10080.00 | x |
| 2019-12-31 | ₩8672.55 | ₩10080.00 | x |
| 2020-12-31 | ₩8880.48 | ₩10080.00 | x |
| 2021-12-31 | ₩9527.51 | ₩10080.00 | x |
| 2022-12-31 | ₩9859.41 | ₩10080.00 | x |
| 2023-12-31 | ₩10333.10 | ₩10080.00 | x |
| 2024-12-31 | ₩10866.27 | ₩10080.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Choong Ang Vaccine Laboratory Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.59%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.02%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.19x
- Recent ROE (6.59%) is above the historical average (6.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 8.24% | 14.47% | 0.49x | 1.17x | ₩-914.44 Million |
| 2015 | 5.93% | 9.40% | 0.56x | 1.13x | ₩-2.23 Billion |
| 2016 | 10.29% | 16.38% | 0.52x | 1.22x | ₩172.74 Million |
| 2017 | 7.08% | 14.37% | 0.39x | 1.26x | ₩-1.89 Billion |
| 2018 | 4.06% | 10.42% | 0.34x | 1.14x | ₩-5.05 Billion |
| 2019 | 2.15% | 5.64% | 0.34x | 1.12x | ₩-6.78 Billion |
| 2020 | 3.61% | 8.71% | 0.35x | 1.20x | ₩-5.59 Billion |
| 2021 | 8.18% | 18.58% | 0.36x | 1.21x | ₩-1.70 Billion |
| 2022 | 4.24% | 10.29% | 0.34x | 1.21x | ₩-5.49 Billion |
| 2023 | 6.01% | 14.33% | 0.35x | 1.20x | ₩-3.98 Billion |
| 2024 | 6.59% | 15.02% | 0.37x | 1.19x | ₩-3.54 Billion |
Industry Comparison
This section compares Choong Ang Vaccine Laboratory Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Choong Ang Vaccine Laboratory Co. Ltd (072020) | ₩104.72 Billion | 8.24% | 0.17x | $63.93 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Choong Ang Vaccine Laboratory Co. Ltd
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Ko… Read more